See more : Chengdu CORPRO Technology Co., Ltd. (300101.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Orchard Therapeutics plc (ORTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orchard Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Fidelis Insurance Holdings Limited (FIHL) Income Statement Analysis – Financial Results
- Kriti Nutrients Limited (KRITINUT.NS) Income Statement Analysis – Financial Results
- Associated British Foods plc (ABF.L) Income Statement Analysis – Financial Results
- Wheels Up Experience Inc. (UP-WT) Income Statement Analysis – Financial Results
- Convertidora Industrial, S.A.B. de C.V. (CONVERA.MX) Income Statement Analysis – Financial Results
Orchard Therapeutics plc (ORTX)
About Orchard Therapeutics plc
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.99M | 483.00K | 2.60M | 2.51M | 2.08M | 0.00 | 0.00 |
| Cost of Revenue | 2.43M | 226.00K | 857.00K | 805.00K | 422.00K | 0.00 | 0.00 |
| Gross Profit | 4.55M | 257.00K | 1.74M | 1.71M | 1.65M | 0.00 | 0.00 |
| Gross Profit Ratio | 65.17% | 53.21% | 66.97% | 67.97% | 79.67% | 0.00% | 0.00% |
| Research & Development | 25.55M | 23.35M | 93.73M | 117.36M | 205.32M | 32.53M | 16.21M |
| General & Administrative | 44.66M | 49.65M | 56.89M | 49.16M | 0.00 | 5.99M | 3.00M |
| Selling & Marketing | 4.14M | 5.26M | 8.09M | 8.06M | 0.00 | 0.00 | 0.00 |
| SG&A | 10.60M | 13.55M | 64.99M | 57.22M | 31.37M | 5.99M | 3.00M |
| Other Expenses | 22.66M | 811.00K | 3.41M | 1.39M | 5.51M | -1.18M | 138.00K |
| Operating Expenses | 36.15M | 36.90M | 158.72M | 174.58M | 236.69M | 38.51M | 19.20M |
| Cost & Expenses | 38.58M | 36.90M | 159.57M | 175.39M | 237.11M | 38.51M | 19.20M |
| Interest Income | 857.00K | 63.00K | 3.19M | 7.36M | 0.00 | 0.00 | 3.00K |
| Interest Expense | 933.00K | 683.00K | 2.33M | 1.54M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.51M | 874.00K | 8.60M | 8.75M | 1.20M | 302.00K | 6.00K |
| EBITDA | -8.08M | -35.54M | -148.38M | -164.12M | -235.03M | -38.21M | -19.20M |
| EBITDA Ratio | -115.65% | -7,358.39% | -5,717.84% | -6,531.00% | -11,321.34% | 0.00% | 0.00% |
| Operating Income | -31.59M | -36.42M | -156.98M | -172.87M | -235.03M | -38.51M | -19.20M |
| Operating Income Ratio | -452.22% | -7,539.34% | -6,049.25% | -6,879.15% | -11,321.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.95M | -3.32M | 4.27M | 7.21M | 5.51M | -1.18M | 138.00K |
| Income Before Tax | -9.01M | -36.22M | -152.71M | -165.66M | -229.53M | -39.69M | -19.07M |
| Income Before Tax Ratio | -129.00% | -7,499.79% | -5,884.78% | -6,592.20% | -11,056.12% | 0.00% | 0.00% |
| Income Tax Expense | -1.13M | 125.00K | -731.00K | -2.24M | 970.00K | 53.00K | 20.00K |
| Net Income | -7.88M | -36.35M | -151.98M | -163.42M | -230.50M | -39.74M | -19.09M |
| Net Income Ratio | -112.84% | -7,525.67% | -5,856.61% | -6,503.06% | -11,102.84% | 0.00% | 0.00% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| Weighted Avg Shares Out | 12.80M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
Orchard Therapeutics Announces Multiple Data Presentations and Publications
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
US approves first gene therapy for rare genetic disease
Source: https://incomestatements.info
Category: Stock Reports